For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240830:nRSd9117Aa&default-theme=true
RNS Number : 9117A Assura PLC 30 August 2024
30 August 2024
Assura plc
Total Voting Rights
In conformity with the FCA's Disclosure Guidance and Transparency Rules DTR
5.6.1 we hereby notify that the company's issued share capital consists of:
Issued shares and voting rights
3,236,951,244 ordinary shares of 10 pence each ("Shares")
The above figure of 3,236,951,244 shares may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, shares
of Assura plc under the FCA's Disclosure and Transparency Rules. No shares are
held in treasury.
- Ends -
For more information, please contact:
Assura plc Tel: 0161 515 2043
David Purcell, Investor Relations Director Email: Investor@assura.co.uk
FGS Global Tel: 0207 251 3801
Gordon Simpson Email: Assura@fgsglobal.com
Notes to Editors
Assura plc is the UK's leading specialist healthcare property investor and
developer. Assura enables better health outcomes through its portfolio of more
than 600 healthcare buildings, from which over six million patients are
served.
A UK REIT based in Altrincham, Assura is a constituent of the FTSE 250 and the
EPRA* indices. As at 31 March 2024, Assura's portfolio was valued at £2.7
billion and has a strong track record of growing financial returns and
dividends for shareholders.
At Assura we BUILD for health and as the first FTSE 250 certified B Corp we
are committed to keeping ESG at the heart of our strategy, creating Healthy
Environments (E) and Healthy Communities (S) and maintaining a Healthy
Business (G).
Further information is available at www.assuraplc.com
(http://www.assuraplc.com)
*EPRA is a registered trademark of the European Public Real Estate Association
Assura plc LEI code: 21380026T19N2Y52XF72
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END TVREAPPNFEKLEEA